Standigm Inc. has disclosed leucine-rich repeat kinase 2 (LRRK2), particularly LRRK2 G2019S mutant, inhibitors reported to be useful for the treatment of cancer, neurodegeneration, rheumatoid arthritis, tuberculosis, axial spondyloarthritis, radiographic (ankylosing spondylitis), Crohn's disease and dyskinesia.